• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomized, placebo-controlled trial 

byOctavio ViramontesandAliya Ramjaun
October 11, 2018
in Chronic Disease, Endocrinology, Gastroenterology, Psychiatry
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

There is a strong relationship between body weight and the risk of developing diabetes. Lorcaserin is a selective serotonin 2C receptor agonist that suppresses appetite, and has been shown to sustain weight loss. This randomized double-blind placebo-controlled trial aimed to evaluate the long-term effects of lorcaserin on diabetes prevention and remission. Patients with a BMI of 27 kg/m2 or higher were randomly assigned to receive either lorcaserin 10 mg twice daily, or matching placebo. All patients had access to a standardized weight management program based on lifestyle modification. Researchers found that 56.8% of patients had diabetes, 33.3% had prediabetes, and 9.9% had normoglycemia. At 1 year, diabetic patients treated with lorcaserin had a net weight loss of 2.6 kg when compared to placebo (95% CI 2.3 kg to 2.9 kg, p<0.0001). Prediabetic patients and those with normoglycemia also experienced significant weight loss compared to placebo (p<0.0001). Lorcaserin resulted in a non-significant increase in the rate of achievement of normoglycemia in patients with prediabetes (9.2% vs. 7.6%, HR 1.20, 95% Cl 0.97 to 1. 49, p=0.093). In patients with diabetes at baseline, severe hypoglycemia was rare, but more common in patients treated with lorcaserin (0.4% vs. 0.1%, p=0.054). This study therefore shows that lorcaserin may decrease the risk of incident diabetes and induce remission of hyperglycemia. 

Click to read the study in The Lancet

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetesLorcaserin
Previous Post

Recurrence of Group B Streptococcal infection similar in shortened and prolonged therapy

Next Post

Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

RelatedReports

Classics Series, Landmark Trials in Medicine
Emergency Classics

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

May 4, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Chronic Disease

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

April 29, 2022
Filtered-sunlight may effectively treat neonatal jaundice in resource-poor settings
Cardiology

Light exposure during sleep may alter glucose metabolism and impair cardiometabolic function

April 19, 2022
Next Post
Food environment associated with gestational diabetes

Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

Tramadol and Celecoxib effective pain control for hysteroscopy

Use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain not linked with adverse outcomes in high risk groups

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.